Solid Biosciences (SLDB) EBITDA (2017 - 2024)
Historic EBITDA for Solid Biosciences (SLDB) over the last 7 years, with Q4 2024 value amounting to -$39.9 million.
- Solid Biosciences' EBITDA fell 7918.71% to -$39.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$129.7 million, marking a year-over-year decrease of 2443.69%. This contributed to the annual value of -$129.7 million for FY2024, which is 2443.69% down from last year.
- Latest data reveals that Solid Biosciences reported EBITDA of -$39.9 million as of Q4 2024, which was down 7918.71% from -$35.2 million recorded in Q3 2024.
- In the past 5 years, Solid Biosciences' EBITDA registered a high of -$19.0 million during Q2 2020, and its lowest value of -$39.9 million during Q4 2024.
- For the 4-year period, Solid Biosciences' EBITDA averaged around -$26.9 million, with its median value being -$26.8 million (2023).
- In the last 5 years, Solid Biosciences' EBITDA skyrocketed by 3558.7% in 2023 and then crashed by 7918.71% in 2024.
- Solid Biosciences' EBITDA (Quarter) stood at -$21.3 million in 2020, then crashed by 61.92% to -$34.6 million in 2022, then surged by 35.59% to -$22.3 million in 2023, then tumbled by 79.19% to -$39.9 million in 2024.
- Its EBITDA was -$39.9 million in Q4 2024, compared to -$35.2 million in Q3 2024 and -$27.8 million in Q2 2024.